RxDoctor Payments Data

Bryant Evans, OD

Optometrist · Lexington, KYNPI 1578979647

Payments from drug & device makers

$2,604in general payments, 2019–2025

Across 50 payments — averaging $52.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Genentech USA, Inc.$525
  • Alcon$415
  • Sun Pharmaceutical Industries Inc.$364
  • Bausch & Lomb Americas Inc.$256
  • Oyster Point Pharma, Inc.$172
  • Notal Vision, Inc.$159
  • plus $713 from 11 others

What the payments were for

  • Speaking & faculty fees$1596%
  • Food & beverage$2,40292%
  • Education$241%
  • Gifts$191%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,604 in reported general payments places this provider in the 80th percentile of 712 optometrist providers in Kentucky.

See all optometrist providers in Kentucky

Medicare billing

Part B allowed, 2024
$90,566
Medicare patients
458
Services billed
1,038

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast67$85,055
RestasisCyclosporine93$80,887
LumiganBimatoprost52$26,142
Cyclosporine28$21,335
RocklatanNetarsudil Mesylat/Latanoprost46$19,441
CombiganBrimonidine Tartrate/Timolol18$12,221
RhopressaNetarsudil Mesylate16$11,228
Latanoprost315$3,104
Prednisolone Acetate47$2,033
Dorzolamide-TimololDorzolamide/Timolol/Pf13$1,992
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat119$1,801
Travoprost23$1,637
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol17$1,563
Tobramycin-DexamethasoneTobramycin/Dexamethasone42$1,483
Dorzolamide Hcl48$746

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieRestasis, Lumigan, Combigan$33$119,250163 claims
Bausch & Lomb Americas Inc.Xiidra$256$85,05567 claims
Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa$87$30,66962 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 712 optometrist providers in Kentucky.

Other optometrist in Lexington

See the full list for Kentucky

Where these figures come from

Is this you, or does something look wrong? →